Vaccination with purified microgamete antigens prevents transmission of rodent malaria
- PMID: 4022122
- DOI: 10.1038/316258a0
Vaccination with purified microgamete antigens prevents transmission of rodent malaria
Abstract
Malaria vaccination with preparations of microgametes has been shown to inhibit transmission of Plasmodium spp. to the mosquito vectors of avian, rodent and simian parasites. This transmission-blocking immunity results from the induction of microgamete-agglutinating antibodies in the vaccinated host which, when ingested in a mosquito blood meal, react with exflagellating microgametes in the midgut to prevent fertilization and oocyst development. Here we have passively transferred the immunity with gamete-specific monoclonal antibodies raised against the rodent malaria parasite Plasmodium yoelii nigeriensis, and an IgG2a isotype monoclonal antibody from a hybridoma cell line, PYG-1, has been used to identify the target antigens on the gametes and to affinity-purify sufficient quantities of specific gamete antigen to facilitate vaccination studies. This transmission-blocking monoclonal antibody immunoprecipitated microgamete antigens of apparent relative molecular mass (Mr), 67K (67,000), 59K, 57K, 42K and 35K. Immunization of mice with these proteins before infection and mosquito feeding led to a 85-99.7% reduction in transmission to the mosquito vector; vaccination via intravenous or intramuscular routes was equally effective and did not require an adjuvant.
Similar articles
-
The Plasmodium yoelii microgamete surface antigen (PyMiGS) induces anti-malarial transmission blocking immunity that reduces microgamete motility/release from activated male gametocytes.Vaccine. 2018 Nov 26;36(49):7463-7471. doi: 10.1016/j.vaccine.2018.10.067. Epub 2018 Oct 26. Vaccine. 2018. PMID: 30420038
-
The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice.Vaccine. 2020 Mar 30;38(15):3129-3136. doi: 10.1016/j.vaccine.2020.02.058. Epub 2020 Mar 5. Vaccine. 2020. PMID: 32147299
-
Vaccination to prevent transmission of Plasmodium yoelii malaria.Parasite Immunol. 1982 Mar;4(2):117-27. doi: 10.1111/j.1365-3024.1982.tb00425.x. Parasite Immunol. 1982. PMID: 7070834
-
Protective antigens of rodent and human bloodstage malaria.Philos Trans R Soc Lond B Biol Sci. 1984 Nov 13;307(1131):171-7. doi: 10.1098/rstb.1984.0117. Philos Trans R Soc Lond B Biol Sci. 1984. PMID: 6151681 Review.
-
Malaria vaccine.Experientia. 1991 Feb 15;47(2):157-63. doi: 10.1007/BF01945417. Experientia. 1991. PMID: 2001717 Review.
Cited by
-
Analysis of immunity induced by the affinity-purified 21-kilodalton zygote-ookinete surface antigen of Plasmodium berghei.Infect Immun. 1991 Jan;59(1):36-44. doi: 10.1128/iai.59.1.36-44.1991. Infect Immun. 1991. PMID: 1987051 Free PMC article.
-
Pfs2400 can mediate antibody-dependent malaria transmission inhibition and may be the Plasmodium falciparum 11.1 gene product.J Exp Med. 1993 Feb 1;177(2):273-81. doi: 10.1084/jem.177.2.273. J Exp Med. 1993. PMID: 8426106 Free PMC article.
-
Status of malaria vaccine research.J R Soc Med. 1989;82 Suppl 17(Suppl 17):52-6. J R Soc Med. 1989. PMID: 2693727 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous